Jason W. Hoskins

Jason W. Hoskins

Auto-generated profile, based on publicly available information

Jason W. Hoskins

Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, 20850, USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
AKAlison P Klein
Alison P Klein
BWBrian M. Wolpin
Brian M. Wolpin
HRHarvey A. Risch
Harvey A. Risch
RSRachael Z. Stolzenberg-Solomon
Rachael Z. Stolzenberg-Solomon
EMEvelina Mocci
Evelina Mocci
LALaufey T. Amundadottir
Laufey T. Amundadottir
In 2020, 146,063 deaths due to pancreatic cancer are estimated to occur in Europe and the United States combined. To identify common susceptibility alleles, we performed the largest pancreatic cancer GWAS to date, including 9040 patients and 12,496 controls of European ancestry from the Pancreatic Cancer Cohort Consortium (PanScan) and the Pancreatic Cancer Case-Control Consortium (PanC4). Here, we find significant evidence of a novel association at rs78417682 (7p12/TNS3, P = 4.35 × 10−8). Replication of 10 promising signals in up to 2737 patients and 4752 controls from the PANcreatic Disease ReseArch (PANDoRA) consortium yields new genome-wide significant loci: rs13303010 at 1p36.33 (NOC2L, P = 8.36 × 10−14), rs2941471 at 8q21.11 (HNF4G, P = 6.60 × 10−10), rs4795218 at 17q12 (HNF1B, P = 1.32 × 10−8), and rs1517037 at 18q21.32 (GRP, P = 3.28 × 10−8). rs78417682 is not statistically significantly associated with pancreatic cancer in PANDoRA. Expression quantitative trait locus analysis in three independent pancreatic data sets provides molecular support of NOC2L as a pancreatic cancer susceptibility gene.

2 February 2012 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
RPRaman Parkesh
Raman Parkesh
JCJessica L. Childs-Disney
Jessica L. Childs-Disney
MNMasayuki Nakamori
Masayuki Nakamori
AKAmit Kumar
Amit Kumar
EWEric Wang
Eric Wang
MDMatthew D. Disney
Matthew D. Disney

1 August 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
MZMingfeng Zhang
Mingfeng Zhang
ZWZhaoming Wang
Zhaoming Wang
OOOfure Obazee
Ofure Obazee
JJJinping Jia
Jinping Jia
ECErica J. Childs
Erica J. Childs
LALaufey T. Amundadottir
Laufey T. Amundadottir
Genome-wide association studies (GWAS) have identified common pancreatic cancer susceptibility variants at 13 chromosomal loci in individuals of European descent. To identify new susceptibility variants, we performed imputation based on 1000 Genomes (1000G) Project data and association analysis using 5,107 case and 8,845 control subjects from 27 cohort and case-control studies that participated in the PanScan I-III GWAS. This analysis, in combination with a two-staged replication in an additional 6,076 case and 7,555 control subjects from the PANcreatic Disease ReseArch (PANDoRA) and Pancreatic Cancer Case-Control (PanC4) Consortia uncovered 3 new pancreatic cancer risk signals marked by single nucleotide polymorphisms (SNPs) rs2816938 at chromosome 1q32.1 (per allele odds ratio (OR) = 1.20, P = 4.88x10 -15), rs10094872 at 8q24.21 (OR = 1.15, P = 3.22x10 -9) and rs35226131 at 5p15.33 (OR = 0.71, P = 1.70x10 -8). These SNPs represent independent risk variants at previously identified pancreatic cancer risk loci on chr1q32.1 ( NR5A2), chr8q24.21 ( MYC) and chr5p15.33 ( CLPTM1L- TERT) as per analyses conditioned on previously reported susceptibility variants. We assessed expression of candidate genes at the three risk loci in histologically normal ( n = 10) and tumor ( n = 8) derived pancreatic tissue samples and observed a marked reduction of NR5A2 expression (chr1q32.1) in the tumors (fold change -7.6, P = 5.7x10 -8). This finding was validated in a second set of paired ( n = 20) histologically normal and tumor derived pancreatic tissue samples (average fold change for three NR5A2 isoforms -31.3 to -95.7, P = 7.5x10 -4-2.0x10 -3). Our study has identified new susceptibility variants independently conferring pancreatic cancer risk that merit functional follow-up to identify target genes and explain the underlying biology.

14 February 2012 in ACS Chemical Biology
Verified
Journal Article
Closed access
JCJessica L. Childs-Disney
Jessica L. Childs-Disney
JHJason Hoskins
Jason Hoskins
SRSuzanne G. Rzuczek
Suzanne G. Rzuczek
CTCharles A. Thornton
Charles A. Thornton
MDMatthew D. Disney
Matthew D. Disney

15 July 2014 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
ZWZhaoming Wang
Zhaoming Wang
BZBin Zhu
Bin Zhu
MZMingfeng Zhang
Mingfeng Zhang
HPHemang Parikh
Hemang Parikh
JJJinping Jia
Jinping Jia
LALaufey T Amundadottir
Laufey T Amundadottir
Genome-wide association studies (GWAS) have mapped risk alleles for at least 10 distinct cancers to a small region of 63 000 bp on chromosome 5p15.33. This region harbors the TERT and CLPTM1L genes; the former encodes the catalytic subunit of telomerase reverse transcriptase and the latter may play a role in apoptosis. To investigate further the genetic architecture of common susceptibility alleles in this region, we conducted an agnostic subset-based meta-analysis (association analysis based on subsets) across six distinct cancers in 34 248 cases and 45 036 controls. Based on sequential conditional analysis, we identified as many as six independent risk loci marked by common single-nucleotide polymorphisms: five in the TERT gene (Region 1: rs7726159, P = 2.10 × 10−39; Region 3: rs2853677, P = 3.30 × 10−36 and PConditional = 2.36 × 10−8; Region 4: rs2736098, P = 3.87 × 10−12 and PConditional = 5.19 × 10−6, Region 5: rs13172201, P = 0.041 and PConditional = 2.04 × 10−6; and Region 6: rs10069690, P = 7.49 × 10−15 and PConditional = 5.35 × 10−7) and one in the neighboring CLPTM1L gene (Region 2: rs451360; P = 1.90 × 10−18 and PConditional = 7.06 × 10−16). Between three and five cancers mapped to each independent locus with both risk-enhancing and protective effects. Allele-specific effects on DNA methylation were seen for a subset of risk loci, indicating that methylation and subsequent effects on gene expression may contribute to the biology of risk variants on 5p15.33. Our results provide strong support for extensive pleiotropy across this region of 5p15.33, to an extent not previously observed in other cancer susceptibility loci.

28 June 2013 in Nature Communications
Verified
Journal Article
Open access
PDF file
JCJessica L. Childs-Disney
Jessica L. Childs-Disney
ESEwa Stepniak-Konieczna
Ewa Stepniak-Konieczna
TTTuan Tran
Tuan Tran
IYIlyas Yildirim
Ilyas Yildirim
HPHaJeung Park
HaJeung Park
MDMatthew D. Disney
Matthew D. Disney
The ability to control pre-mRNA splicing with small molecules could facilitate the development of therapeutics or cell-based circuits that control gene function. Myotonic dystrophy type 1 is caused by the dysregulation of alternative pre-mRNA splicing due to sequestration of muscleblind-like 1 protein (MBNL1) by expanded, non-coding r(CUG) repeats (r(CUG)exp). Here we report two small molecules that induce or ameliorate alternative splicing dysregulation. A thiophene-containing small molecule (1) inhibits the interaction of MBNL1 with its natural pre-mRNA substrates. Compound (2), a substituted naphthyridine, binds r(CUG)exp and displaces MBNL1. Structural models show that 1 binds MBNL1 in the Zn-finger domain and that 2 interacts with UU loops in r(CUG)exp. This study provides a structural framework for small molecules that target MBNL1 by mimicking r(CUG)exp and shows that targeting MBNL1 causes dysregulation of alternative splicing, suggesting that MBNL1 is thus not a suitable therapeutic target for the treatment of myotonic dystrophy type 1.